Irvine-based drug maker Allergan Inc. said it plans to cut some 160 jobs from its operations at Mougins, France, and other European locations.
The jobs primarily are in research and development, plus some sales and administration workers.
Allergan previously had said it would consolidate its European R & D; functions in a bid to cut costs and reinvest money into the business in order to reduce the time it takes to bring a drug to market.
Allergan said it would take a charge of $40 million to $53 million before taxes. The drug maker expects the move to reduce its operating costs between $6 million and $9 million yearly.
The drug maker will move work to its Irvine home base, along with plants in High Wycombe, U.K. and Dublin, Ireland.
